MADISON, Wis.--(BUSINESS WIRE)--Stratatech Corp., a privately-held regenerative medicine company, today announced that it has genetically modified its StrataGraft® living human skin substitute to actively fight costly bacterial infections that routinely develop at the site of burns and other severe skin injuries, such as skin ulcers. Bacterial infection is a primary cause of skin graft rejection and can significantly increase the hospital costs of burn and other skin injury patients. Stratatech’s skin-substitute innovation, detailed in an article published online this morning by the journal Molecular Therapy, enables the immediate topical delivery of a potent anti-infective that actively inhibits bacterial growth and promotes regrowth of the patient’s own cells.
